[Chemotherapy of testicular cancer].

Abstract

Platinum-based polychemotherapy has increased the cure rate in testicular cancer dramatically: at first, chemotherapy was mainly used in advanced disease. Recently it has also become common in low-stage disease, though other therapeutic options are equivalent. Risk factors might help to find the right decision. The success of treatment in patients with metastatic disease results from the combination of chemotherapy and secondary surgery. High-dose chemotherapy for patients with poor prognosis or recurrent disease is being evaluated in clinical trials. Concerning the success in these stages prognostic factors are of special importance. Patients with advanced-stage nonseminoma need residual tumor resection after chemotherapy if no complete remission could be achieved. The therapist should be aware of the indication for and schedule of chemotherapy, its side effects, and supportive care.

• Authors: S Krege, J T Hartmann, H Rübben
• Journal: Der Urologe. Ausg. A (Urologe A) Vol. 45 Issue 5 Pg. 600-4 (May 2006) ISSN: 0340-2592 [Print] Germany
• Vernacular Title: Chemotherapie des Hodentumors.
• PMID: 16612645 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (therapeutic use)
• Clinical Trials as Topic
• Humans
• Male
• Neoplasm Recurrence, Local (prevention & control)
• Palliative Care (methods)
• Practice Guidelines as Topic
• Practice Patterns, Physicians'
• Terminal Care (methods)
• Testicular Neoplasms (drug therapy, secondary)